These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 222523)

  • 1. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF).
    Lum CT; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835
    [No Abstract]   [Full Text] [Related]  

  • 3. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
    Svendsen KR; Overgaard-Hansen K; Frederiksen S
    Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine and hypoxic vasodilatation.
    Dóra E
    J Cereb Blood Flow Metab; 1985 Dec; 5(4):621-4. PubMed ID: 3877069
    [No Abstract]   [Full Text] [Related]  

  • 5. Suppression of human lymphocyte DNA and protein synthesis in vitro by adenosine and eight modified adenine nucleosides in the presence or in the absence of adenosine deaminase inhibitors, 2'-deoxycoformycin (DCF) and erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA).
    Ratech H; Kuritsky L; Thorbecke GJ; Hirschhorn R
    Cell Immunol; 1982 Apr; 68(2):244-51. PubMed ID: 6980056
    [No Abstract]   [Full Text] [Related]  

  • 6. Adenosine deaminase inhibitors enhance cerebral anoxic hyperemia in the rat.
    Phillis JW; DeLong RE; Towner JK
    J Cereb Blood Flow Metab; 1985 Jun; 5(2):295-9. PubMed ID: 3872875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of adenosine deaminase inhibitors on lymphocyte-mediated cytolysis.
    Wolberg G; Zimmerman TP
    Ann N Y Acad Sci; 1985; 451():215-26. PubMed ID: 3878118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
    Smith CM; Belch A; Henderson JF
    Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro effects of adenosine deaminase inhibitors on lymphocyte mitogen responsiveness in the mouse.
    Ballow M; Pantschenko AG
    Cell Immunol; 1981 Oct; 64(1):29-43. PubMed ID: 6975175
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of adenosine deaminase inhibitors on the heart's functional and biochemical recovery from ischemia: a study utilizing the isolated rat heart adapted to 31P nuclear magnetic resonance.
    Dhasmana JP; Digerness SB; Geckle JM; Ng TC; Glickson JD; Blackstone EH
    J Cardiovasc Pharmacol; 1983; 5(6):1040-7. PubMed ID: 6196552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme inhibition titration assay for 2'-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats.
    Chassin MM; Adamson RH; Zaharevitz DW; Johns DG
    Biochem Pharmacol; 1979 Jun; 28(12):1849-55. PubMed ID: 454456
    [No Abstract]   [Full Text] [Related]  

  • 13. Adenosine deaminase inhibitors. Synthesis of deaza analogues of erythro-9-(2-hydroxy-3-nonyl)adenine.
    Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S; Lupidi G; Riva F
    J Med Chem; 1984 Mar; 27(3):274-8. PubMed ID: 6699873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition.
    Bessodes M; Bastian G; Abushanab E; Panzica RP; Berman SF; Marcaccio EJ; Chen SF; Stoeckler JD; Parks RE
    Biochem Pharmacol; 1982 Mar; 31(5):879-82. PubMed ID: 7082355
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of brain adenosine deaminase by 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl) adenine.
    Skolnick P; Nimitkitpaisan Y; Stalvey L; Daly JW
    J Neurochem; 1978 Jun; 30(6):1479-82. PubMed ID: 670988
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA).
    Lum CT; Schmidtke JR; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1978 Jul; 10(3):258-61. PubMed ID: 307473
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice.
    Lambe CU; Nelson DJ
    Biochem Pharmacol; 1982 Feb; 31(4):535-9. PubMed ID: 7066021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Cancer Res; 1979 Sep; 39(9):3655-60. PubMed ID: 476690
    [No Abstract]   [Full Text] [Related]  

  • 19. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
    Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
    Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
    Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
    Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.